UBS Group
KNSA icon

UBS Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

UBS Group’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.36M Sell
69,700
-8,216
-11% -$364K ﹤0.01% 4474
2025
Q4 		$3.21M Buy
77,916
+28,099
+56% +$1.13M ﹤0.01% 4483
2025
Q3 		$1.93M Buy
49,817
+19,201
+63% +$624K ﹤0.01% 4983
2025
Q2 		$847K Sell
30,616
-19,373
-39% -$493K ﹤0.01% 5587
2025
Q1 		$1.11M Sell
49,989
-8,609
-15% -$177K ﹤0.01% 5193
2024
Q4 		$1.16M Buy
58,598
+9,091
+18% +$207K ﹤0.01% 5194
2024
Q3 		$1.24M Buy
+49,507
New +$1.21M ﹤0.01% 4459
2024
Q2 		– Sell
-104,762
Closed -$2.07M – 9829
2024
Q1 		$2.07M Buy
104,762
+19,346
+23% +$378K ﹤0.01% 3928
2023
Q4 		$1.5M Buy
85,416
+22,602
+36% +$371K ﹤0.01% 4114
2023
Q3 		$1.09M Buy
62,814
+18,171
+41% +$306K ﹤0.01% 3991
2023
Q2 		$629K Sell
44,643
-6,672
-13% -$89.3K ﹤0.01% 4633
2023
Q1 		$552K Sell
51,315
-5,790
-10% -$76.3K ﹤0.01% 4606
2022
Q4 		$855K Buy
+57,105
New +$831K ﹤0.01% 4223
2022
Q2 		– Sell
-1,173
Closed -$12K – 10640
2022
Q1 		$12K Sell
1,173
-75,302
-98% -$798K ﹤0.01% 8187
2021
Q4 		$900K Sell
76,475
-6,262
-8% -$77K ﹤0.01% 4485
2021
Q3 		$942K Buy
82,737
+62,718
+313% +$817K ﹤0.01% 4246
2021
Q2 		$279K Sell
20,019
-15,624
-44% -$237K ﹤0.01% 5130
2021
Q1 		$660K Buy
35,643
+34,276
+2,507% +$701K ﹤0.01% 4640
2020
Q4 		$24K Sell
1,367
-1,143
-46% -$20.1K ﹤0.01% 6805
2020
Q3 		$38K Sell
2,510
-8,141
-76% -$153K ﹤0.01% 5838
2020
Q2 		$271K Buy
10,651
+3,441
+48% +$71.9K ﹤0.01% 4586
2020
Q1 		$112K Sell
7,210
-11,758
-62% -$184K ﹤0.01% 5193
2019
Q4 		$210K Buy
18,968
+9,604
+103% +$83.5K ﹤0.01% 5571
2019
Q3 		$80K Buy
9,364
+7,629
+440% +$84.3K ﹤0.01% 5899
2019
Q2 		$23K Buy
+1,735
New +$26.9K ﹤0.01% 6516
2018
Q4 		– Sell
-1,530
Closed -$39K – 8168
2018
Q3 		$39K Buy
+1,530
New +$29.8K ﹤0.01% 6350

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

UBS Group's KNSA Position: Q1 2026 in Review

UBS Group reduced its Kiniksa Pharmaceuticals (KNSA) stake by 11% in Q1 2026, selling an estimated $364K and leaving 69,700 shares worth $3.36M. The position accounts for ﹤0.01% of the portfolio, ranked #4474.

UBS Group first reported a position in KNSA in Q3 2018 and has held it in 26 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • UBS Group held 69,700 shares of Kiniksa Pharmaceuticals worth $3.36M as of Q1 2026.
  • UBS Group sold 8,216 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $364K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4474 holding.
  • UBS Group first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 26 quarters since.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.